These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 19544224)

  • 21. Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist?
    Zoulim F
    Hepatology; 2006 Dec; 44(6):1404-7. PubMed ID: 17133478
    [No Abstract]   [Full Text] [Related]  

  • 22. Immediate allergy, drug-induced eruption, by entecavir.
    Sugiura K; Sugiura M; Takashi T; Naoki H; Itoh A
    J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):487-9. PubMed ID: 18721215
    [No Abstract]   [Full Text] [Related]  

  • 23. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China.
    Yao G
    J Antimicrob Chemother; 2007 Aug; 60(2):201-5. PubMed ID: 17556353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA notifications. FDA revises Baraclude labeling for HIV patients.
    AIDS Alert; 2007 Sep; 22(9):103-4. PubMed ID: 18415955
    [No Abstract]   [Full Text] [Related]  

  • 26. Is entecavir ideal for the treatment of lamivudine-refractory chronic hepatitis B?
    Su CW; Wu JC; Lee SD
    Hepatology; 2008 Nov; 48(5):1726-7; author reply 1727-8. PubMed ID: 18972445
    [No Abstract]   [Full Text] [Related]  

  • 27. Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: which method should be used?
    Degertekin B; Lok AS
    J Hepatol; 2008 Jun; 48(6):892-4. PubMed ID: 18433924
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
    Schiff E; Simsek H; Lee WM; Chao YC; Sette H; Janssen HL; Han SH; Goodman Z; Yang J; Brett-Smith H; Tamez R
    Am J Gastroenterol; 2008 Nov; 103(11):2776-83. PubMed ID: 18721244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
    Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
    Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seroclearance of Hepatitis B surface antigen after entecavir treatment.
    Halichidis S; Dumea E; Cambrea CS
    J Gastrointestin Liver Dis; 2013 Jun; 22(2):236. PubMed ID: 23799228
    [No Abstract]   [Full Text] [Related]  

  • 31. Entecavir for the treatment of chronic hepatitis B virus infection.
    Matthews SJ
    Clin Ther; 2006 Feb; 28(2):184-203. PubMed ID: 16678641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Case-controlled study of entecavir treatment for chronic severe hepatitis B].
    Xiao GM; He KY; Jia WD; Lei CL; Yang Z
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Feb; 23(1):56-8. PubMed ID: 19799020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Entecavir: a new treatment option for chronic hepatitis B.
    Zoulim F
    J Clin Virol; 2006 May; 36(1):8-12. PubMed ID: 16515882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Entecavir results in undetectable HBV in patients restarting treatment.
    AIDS Patient Care STDS; 2007 May; 21(5):370. PubMed ID: 17549811
    [No Abstract]   [Full Text] [Related]  

  • 36. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
    Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
    J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maculopapular-type drug eruption caused by entecavir.
    Yamada S; Sawada Y; Nakamura M
    Eur J Dermatol; 2011; 21(4):635-6. PubMed ID: 21697053
    [No Abstract]   [Full Text] [Related]  

  • 38. Effective treatment for de novo hepatitis B with nucleotide analogue in patients with hematological malignancies.
    Ueda Y; Marusawa H; Ichinohe T; Kadowaki N; Uchiyama T; Chiba T
    Am J Hematol; 2009 May; 84(5):315-6. PubMed ID: 19350661
    [No Abstract]   [Full Text] [Related]  

  • 39. Entecavir (Bristol-Myers Squibb).
    Billich A
    Curr Opin Investig Drugs; 2001 May; 2(5):617-21. PubMed ID: 11569933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A study of the dosage and efficacy of entecavir for treating hepatitis B virus].
    Yao GB; Zhang DF; Wang BE; Xu DZ; Zhou XQ; Lei BJ
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):484-7. PubMed ID: 16042878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.